Stay up to date on COVID-19. Learn more
October 2, 2024
The changing landscape of multiple myeloma – Toronto Star
September is Blood CancerA term for diseases in which malignant cells divide without control. Cancer cells can invade nearby tissues and spread through the bloodstream and lymphatic system to other parts of the body. Awareness Month — an important time to spotlight the impact of blood cancers on the lives of Canadians. While many people are familiar with blood cancers like leukemia, they may not know that multiple myeloma is the second most prevalent blood cancer in Canada and is predicted[…]
Learn moreOctober 2, 2024
“I knew something was wrong”: A Terrebonne woman has to go back to the doctor six times to be diagnosed with blood cancer – Journal de Montreal (in French only)
A Terrebonne woman who had to go to the doctor six times before being diagnosed with blood cancer in 2013 is using her remission to raise awareness of this insidious disease and prevent other sufferers from being ignored. “I didn’t have a family doctor at the time and had to go[…]
Learn moreSeptember 19, 2024
The Government of Canada introduces the Connected Care for Canadians Act
On June 6, 2024, the Honourable Mark Holland, Minister of Health, introduced Bill C-72 the Connected Care for Canadians Act. This Act is about enabling Canadians to securely access their own health data, which will empower patient’s decision-making and improve the care they receive from health providers in Canada. This Act outlines[…]
Learn moreJune 21, 2024
INESSS recommends including Tecvayli
On June 5, 2024, the Institut national d’excellence en santé et en services sociaux (INESSS) formally recommended to the Minister that Tecvayli (teclistamab) be included in the list of medications at treatment centres for the treatment of patients with relapsed or refractoryDisease that is unresponsive to standard treatments. multiple myeloma, subject to specific conditions. Read more here[…]
Learn moreJune 20, 2024
Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma
To date, identifying high-risk SMM patients remains an important clinicalInvolving direct observation of a patient. need. In this study, we present the 3-dimensional telomere profiling as a structural biomarker capable of stratifying SMM patients as a function of genomic instability Read more… […]
Learn moreMay 24, 2024
CCTG Recruiting for a Patient Representative Volunteer Role
The Canadian Cancer Trial Group (CCTG) is currently seeking applications for a Patient Representative for the Hematology Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. We encourage applications from all qualified candidates and will accommodate applicants’ needs throughout all stages of the recruitment and[…]
Learn moreMyeloma Canada updates
September 24, 2024
Multiple myeloma: research update
Myeloma Canada, along with thousands from the global hematology community, had the privilege of following the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 – June 3) and the European Hematology Association (EHA) Hybrid Congress (June 13-16) to hear from leading myeloma experts about the latest progress in[…]
Learn moreSeptember 19, 2024
Myeloma Canada at the CDA-AMC Symposium 2024
Canada’s Drug Agency (CDA-AMC) Symposium 2024 is a 3-day hybrid event in Ottawa (ON) that gathers leaders from across Canada with expertise in policy, industry, health technology assessment, patient advocacy, medicine, public health, and communications. Representing Myeloma Canada were Martine Elias – CEO; Jessy Ranger – Director, Health Policy, Advocacy[…]
Learn moreJuly 17, 2024
Letter to the Editor: The best of science and the worst of bureaucracy
We invite you to read our opinion letter, written by Jessy Ranger, Director, Patient Programs, Health Policy & Advocacy at Myeloma Canada, and Christina Sit, Manager, Community and Strategic Partnerships at The Leukemia & Lymphoma Society of Canada, on the issues of access to treatment and care. As the country’s[…]
Learn moreJuly 16, 2024
Advocacy activities recap 2023
At first, engaging in advocacy initiatives involving government bodies, officials, drug agencies, and various stakeholders invested in improving the healthcare system or treatment accessibility may appear abstract or a little daunting. Nevertheless, numerous organizations, such as ours, are inherently suited to negotiate, influence and persuade those who have the authority[…]
Learn moreJune 21, 2024
Martine Elias summarizes Real World Evidence (RWE) session at 2024 Myeloma Patients Europe Masterclass
As proud members of Myeloma Patients Europe (MPe), Myeloma Canada attended – and presented at – MPe’s annual Masterclass this past May. The Masterclass is a one-and-a-half-day educational program designed to: increase the knowledge and skills of MPe’s members; share the latest updates on myeloma and amyloidosisA condition in which myeloma light chains (Bence Jones proteins) are deposited in tissues and organs throughout the body. This occurs more commonly with lambda versus kappa Bence Jones proteins. In patients with amyloidosis, the light chain proteins bind to certain tissues such as heart, nerves and kidney rather than being excreted out of the body through the kidneys. diagnosisThe process of identifying a disease by its signs and symptoms., treatment and care; discuss the[…]
Learn moreMay 2, 2024
A round of applause for Martine and her new role!
It is with great joy and pleasure that we announce the advancement of our well-regarded Executive Director, Martine Elias, to the distinguished position of CEO at Myeloma Canada. Martine has been the driving force behind numerous achievements and advancements that have shaped Myeloma Canada into the leading organization it is today.[…]
Learn more